Johnson & Johnson (JNJ)vsPetMed Express Inc (PETS)
JNJ
Johnson & Johnson
$275.19
+1.53%
HEALTHCARE · Cap: $615.87B
PETS
PetMed Express Inc
$1.19
+0.85%
HEALTHCARE · Cap: $26.45M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 58728% more annual revenue ($99.33B vs $168.86M). JNJ leads profitability with a 16.2% profit margin vs -17.3%. PETS appears more attractively valued with a PEG of 2.32. JNJ earns a higher WallStSmart Score of 57/100 (C).
JNJ
Buy57
out of 100
Grade: C
PETS
Hold43
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-83.0%
Fair Value
$144.12
Current Price
$275.19
$131.07 premium
Margin of Safety
+70.3%
Fair Value
$10.00
Current Price
$1.19
$8.81 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 25.1%
Generating 6.4B in free cash flow
Reasonable price relative to book value
Earnings expanding 266.7% YoY
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 96.0%
Expensive relative to growth rate
Smaller company, higher risk/reward
Weak financial health signals
ROE of -100.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.1%.
Bull Case : PETS
The strongest argument for PETS centers on Price/Book, EPS Growth, Debt/Equity.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Bear Case : PETS
The primary concerns for PETS are PEG Ratio, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
JNJ profiles as a mature stock while PETS is a turnaround play — different risk/reward profiles.
PETS carries more volatility with a beta of 0.84 — expect wider price swings.
JNJ is growing revenue faster at 5.9% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 43/100), backed by strong 16.2% margins. PETS offers better value entry with a 70.3% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →PetMed Express Inc
HEALTHCARE · PHARMACEUTICAL RETAILERS · USA
PetMed Express, Inc., doing business as 1-800-PetMeds, is a pet pharmacy in the United States. The company is headquartered in Delray Beach, Florida.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?